ArticleFrontiers in endocrinology2025
Development and validation of a collagen signature to predict central lymph node metastasis in papillary thyroid cancer.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current clinicopathological risk factors lack the precision necessary for accurate prediction of central lymph node metastasis (CLNM) in patients with papillary thyroid cancer (PTC). Structural remodeling of the tumor microenvironment (TME), particularly collagen organization, may play a pivotal role in metastatic dissemination. Objective: The objective of this study was to develop a collagen signature within the TME to predict CLNM in PTC and validate that the new model incorporating it into the assessment alongside clinicopathological risk factors would enhance the predictive accuracy. Methods: In this retrospective study, we included 350 patients with classic PTC, all of whom underwent thyroidectomy with prophylactic central lymph node dissection. The cases were randomly assigned to a training cohort and a testing cohort with a 6:4 ratio. A total of 142 collagen features in the TME were extracted from second harmonic generation images of tumor specimens. We constructed a collagen signature using a least absolute shrinkage and selection operator (LASSO) regression model. Multivariate logistic regression was used to integrate the signature with clinicopathological variables and construct a nomogram. Results: The predictive ability of collagen signature was also validated by AUC of 0.821 in training cohort and AUC of 0.793 in testing cohort. The collagen signature remained an independent predictor after adjustment for tumor size, capsular invasion, and tumor location in the multivariate analysis. Furthermore, the integrated model showed superior predictive performance compared to the clinicopathological model alone (0.842 vs. 0.679, Conclusions: The collagen signature within the TME represents a promising new biomarker that can effectively predict CLNM in PTC patients, potentially improving clinical decision-making and patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.